LENZ Therapeutics
LENZ
160 hedge funds and large institutions have $562M invested in LENZ Therapeutics in 2025 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 53 increasing their positions, 33 reducing their positions, and 56 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 33
9.91% more ownership
Funds ownership: 102.17% → 112.08% (+9.9%)
4% less funds holding
Funds holding: 166 → 160 (-6)
11% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 56
48% less call options, than puts
Call options by funds: $2.74M | Put options by funds: $5.28M
59% less capital invested
Capital invested by funds: $1.36B → $562M (-$794M)
67% less funds holding in top 10
Funds holding in top 10: 9 → 3 (-6)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$105M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.5M |
| 3 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$16.6M |
| 4 |
Millennium Management
New York
|
+$15.7M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$14.8M |
Top Sellers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$50M |
| 2 |
RI
RTW Investments
New York
|
-$40.2M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$32.3M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$29.2M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$17.1M |
LENZ Hedge Fund Activity: Q4 2025 in Review
160 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q4 2025, worth a combined $562M — down 59% from $1.36B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of LENZ and 50 opened new positions — a net loss of 6 holders — while 33 trimmed existing stakes and 53 added.
The largest buyer was Fidelity Investments, adding an estimated $105M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $50M sold.
- 160 institutional investors held LENZ Therapeutics (LENZ) as of Q4 2025, down from 166 in Q3 2025.
- Funds reported $562M of LENZ Therapeutics stock for Q4 2025, down 59% quarter-over-quarter.
- 50 funds opened new LENZ Therapeutics positions in Q4 2025 and 56 closed out, a net change of -6 holders.
- The largest LENZ Therapeutics buyer in Q4 2025 was Fidelity Investments, an estimated $105M added.
- The largest LENZ Therapeutics seller in Q4 2025 was Paradigm Biocapital Advisors, an estimated $50M sold.
Based on aggregated 13F filings for Q4 2025.